4 completed, 2 recruiting, 1 not yet recruiting, 1 terminated. 2 Not applicable, 2 Phase 1, 1 Early Phase 1, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 2 | Completed 1, Not yet recruiting 1 |
| Phase 1 | 2 | Completed 1, Recruiting 1 |
| Early Phase 1 | 1 | Terminated 1 |
| Phase 4 | 1 | Completed 1 |
Follow Adenocarcinoma Pancreas: new trials by email Literature Review of Adenocarcinoma Pancreas trials Research Report on Adenocarcinoma Pancreas
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Spleen Preservation Versus Splenectomy in Left Pancreatectomy for Pancreatic Ductal Adenocarcinoma (SPLENDID) SPLP, LPS - Pancreatic Cancer, Pancreatectomy | Not applicable | Not yet recruiting | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | 360 | 2026-11-01 | 2026-09-02 |
| Pressurized Intraperitoneal Aerosolized Chemotherapy (PIPAC) in Patients With Peritoneal Metastasis From Pancreatic Adenocarcinoma PIPAC, Nab-paclitaxel - Adenocarcinoma Pancreas | Phase 1 | Recruiting | Northwell Health | 10 | 2026-01-11 | 2026-06-03 |
| FAPi PET in Pancreatic Ductal Adenocarcinoma Ga-68 FAPi PET/CT - Pancreatic Cancer, Adenocarcinoma Pancreas | Recruiting | Tata Memorial Hospital | 60 | 2025-01-04 | 2026-01-15 | |
| Geriatric Assessment Directed Trial to Evaluate Gemcitabine +/- Nab-paclitaxel in Elderly Pancreatic Cancer Patients Nab-paclitaxel, Gemcitabine, Best Supportive Care - Adenocarcinoma Pancreas | Phase 4 | Completed | AIO-Studien-gGmbH | 32 | 2016-06-01 | 2021-08-10 |
| Evaluation of PET/MRI in Patients With Pancreatic Adenocarcinoma PET/MRI - Adenocarcinoma Pancreas | Not applicable | Completed | Washington University School of Medicine | 25 | 2013-02-01 | 2018-06-25 |
| Pilot, Neoadjuvant Gemcitabine and Abraxane Chemotherapy Followed by Surgery, Adenocarcinoma of the Pancreas Surgery, Genetic Expression, Chemotherapy - Adenocarcinoma Pancreas | Early Phase 1 | Terminated | Medical University of South Carolina | 2 | 2012-07-01 | 2016-03-08 |
| Phase 1 Study of Preoperative Gemcitabine Plus CP-870, 893 Followed by Addition of CP-870,893 to Standard -Of-care Adjuvant Chemoradiation for Patients With Newly Diagnosed Resectable Pancreatic Carcinoma Gemcitabine, CP-870,893 - Adenocarcinoma Pancreas | Phase 1 | Completed | Abramson Cancer Center at Penn Medicine | 10 | 2012-04-01 | 2018-08-27 |
| Contrast Enhanced Harmonic Endoscopic Ultrasound (CEH-EUS) in Focal Pancreatic Masses Adenocarcinoma Pancreas, Chronic Pancreatitis | Completed | University of Medicine and Pharmacy Craiova | 210 | 2011-03-01 | 2018-01-17 |
Pancreatic Neoplasms (2) · Adenocarcinoma (1) · Pancreatitis, Chronic (1)
Digestive System Diseases (3) · Neoplasms (3) · Pancreatic Diseases (3) · Digestive System Neoplasms (2) · Endocrine Gland Neoplasms (2) · Endocrine System Diseases (2) · Neoplasms by Site (2) · Carcinoma (1) · Chronic Disease (1) · Disease Attributes (1) · Neoplasms by Histologic Type (1) · Neoplasms, Glandular and Epithelial (1) · Pancreatitis (1) · Pathologic Processes (1) · Pathological Conditions, Signs and Symptoms (1)
Gemcitabine (3) · 130-nm albumin-bound paclitaxel (2) · Albumin-Bound Paclitaxel (2) · Drug Therapy (1) · Surgical Procedures, Operative (1) · selicrelumab (1)
AIO-Studien-gGmbH (1) · Abramson Cancer Center at Penn Medicine (1) · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) (1) · Medical University of South Carolina (1) · Northwell Health (1) · Tata Memorial Hospital (1) · University of Medicine and Pharmacy Craiova (1) · Washington University School of Medicine (1)
United States (4) · Germany (2) · Denmark (1) · France (1) · India (1) · Italy (1) · Netherlands (1) · Norway (1) · Romania (1) · Spain (1) · United Kingdom (1)
Ameya Puranik, DNB (1) · Eric Kimchi, MD (1) · Jony van Hilst, MD, PhD (1) · Marc G. Besselink, MD, PhD (1) · Matthias Ebert, Prof. (1) · Mohammad Abu Hilal, MD, PhD (1) · Robert Vonderheide, MD, DPhil (1) · Ryan C. Fields, MD (1)